Advertisement
Interested parties may access the live webcast by visiting the Company's website at www.ondinebiopharma.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be required to join the webcast. An audio archive of the presentation will be available for approximately 60 days.
Advertisement
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development facility in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com
Forward-Looking Statements:
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.
SOURCE Ondine Biopharma Corporation
